DK3658147T3 - Kombination, som omfatter palbociclib og 6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylsyre, og dens anvendelse til behandling af cancer - Google Patents

Kombination, som omfatter palbociclib og 6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylsyre, og dens anvendelse til behandling af cancer Download PDF

Info

Publication number: DK3658147T3
Authority: DK; Denmark
Prior art keywords: annulene; oxyphenyl; fluoropropyl; pyrrolidin; dichlorophenyl
Prior art date: 2017-07-24

Application number

DK18740615.2T

Other languages

English (en)

Inventor

Monsif Bouaboula

Maysoun Shomali

Fangxian Sun

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-07-24

Filing date

2018-07-23

Publication date

2022-01-31

2018-07-23 Application filed by Sanofi Sa filed Critical Sanofi Sa

2022-01-31 Application granted granted Critical

2022-01-31 Publication of DK3658147T3 publication Critical patent/DK3658147T3/da

Links

KISZAGQTIXIVAR-VWLOTQADSA-N 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid Chemical compound ClC1=C(C=CC(=C1)Cl)C1=C(C2=C(CCC1)C=C(C=C2)C(=O)O)C1=CC=C(C=C1)O[C@@H]1CN(CC1)CCCF KISZAGQTIXIVAR-VWLOTQADSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 title 1
229960004390 palbociclib Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK18740615.2T 2017-07-24 2018-07-23 Kombination, som omfatter palbociclib og 6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylsyre, og dens anvendelse til behandling af cancer DK3658147T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762536121P	2017-07-24	2017-07-24
EP17305998.1A EP3434272A1 (en)	2017-07-25	2017-07-25	Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
PCT/EP2018/069901 WO2019020559A1 (en)	2017-07-24	2018-07-23	COMBINATION COMPRISING PALBOCICLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] OXYPHENYL] -8,9-DIHYDRO ACID -7H-BENZO [7] ANNULENE-2-CARBOXYLIC AND ITS USE FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number	Publication Date
DK3658147T3 true DK3658147T3 (da)	2022-01-31

Family

ID=59569252

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18740615.2T DK3658147T3 (da)	2017-07-24	2018-07-23	Kombination, som omfatter palbociclib og 6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylsyre, og dens anvendelse til behandling af cancer

Country Status (30)

Country	Link
US (2)	US11260057B2 (da)
EP (2)	EP3434272A1 (da)
JP (1)	JP6741897B1 (da)
KR (1)	KR20200031622A (da)
CN (1)	CN111107851B (da)
AR (1)	AR112284A1 (da)
AU (1)	AU2018308871A1 (da)
BR (1)	BR112020001398A2 (da)
CA (1)	CA3070754A1 (da)
CO (1)	CO2020000240A2 (da)
DK (1)	DK3658147T3 (da)
ES (1)	ES2906279T3 (da)
HR (1)	HRP20212030T1 (da)
HU (1)	HUE057271T2 (da)
IL (1)	IL272166B2 (da)
LT (1)	LT3658147T (da)
MA (1)	MA49673B1 (da)
MX (1)	MX393852B (da)
MY (1)	MY195271A (da)
PH (1)	PH12020500091A1 (da)
PL (1)	PL3658147T3 (da)
PT (1)	PT3658147T (da)
RS (1)	RS62837B1 (da)
RU (1)	RU2764116C2 (da)
SG (1)	SG11202000367RA (da)
SI (1)	SI3658147T1 (da)
TW (1)	TWI768087B (da)
UY (1)	UY37818A (da)
WO (1)	WO2019020559A1 (da)
ZA (1)	ZA202000145B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3434272A1 (en) *	2017-07-25	2019-01-30	Sanofi	Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
ES2923412T3 (es) *	2018-09-07	2022-09-27	Sanofi Sa	Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
AU2020268762A1 (en) *	2019-05-09	2021-12-02	Sanofi	6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
JP7680438B2 (ja)	2019-10-01	2025-05-20	サノフイ	新規の置換６，７－ジヒドロ－５ｈ－ベンゾ［７］アンヌレン化合物、その製造方法およびその治療的使用
BR112022009705A2 (pt) *	2019-12-09	2022-08-09	Sanofi Sa	Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica
TW202146007A (zh) *	2020-02-27	2021-12-16	法商賽諾菲公司	包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
AU2021366223A1 (en)	2020-10-19	2023-06-22	Sanofi	Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
US12595230B2 (en)	2020-10-19	2026-04-07	Sanofi	Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
IL303041A (en) *	2020-11-23	2023-07-01	Sanofi Sa	Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
TW202302084A (zh) *	2021-03-02	2023-01-16	法商賽諾菲公司	以安森司坦和帕博西尼治療乳癌
TW202304425A (zh) *	2021-04-12	2023-02-01	法商賽諾菲公司	包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
KR102815360B1 (ko)	2022-03-03	2025-06-02	인하대학교 산학협력단	암의 예방 또는 치료용 조성물
US12558428B2 (en)	2024-03-08	2026-02-24	Halda Therapeutics Opco, Inc.	Heterobifunctional compounds and their use in treating disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2105655A1 (en)	1991-03-08	1992-09-09	Kent Neuenschwander	Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de)	1998-07-18	2000-01-20	Schering Ag	Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2236056T3 (es)	2001-01-24	2005-07-16	Chiesi Farmaceutici S.P.A.	Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
CZ2004220A3 (cs)	2001-08-11	2004-06-16	Bristol-Myers Squibb Pharma Company	Název neuveden
SI1501819T1 (sl)	2002-04-24	2011-01-31	Merck Sharp & Dohme	Modulatorji estrogen receptorjev
CA2512000C (en)	2002-12-26	2011-08-09	Eisai Co., Ltd.	Selective estrogen receptor modulator
AU2005267385B2 (en)	2004-06-25	2011-11-10	Janssen Pharmaceutica N.V.	Quaternary salt CCR2 antagonists
ES2551086T3 (es)	2005-06-14	2015-11-16	Baylor University	Análogos de combretastatina con actividad de unión a tubulina
US8127618B1 (en)	2007-05-18	2012-03-06	Pacesetter, Inc.	Implantable micro-electromechanical system sensor
EP2048126A1 (de)	2007-10-11	2009-04-15	Bayer Schering Pharma AG	Benzocycloheptanderivate als selektiv wirksame Estrogene
DE102010030538A1 (de)	2010-06-25	2011-12-29	Bayer Schering Pharma Aktiengesellschaft	6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en)	2010-09-16	2012-08-29	Aragon Pharmaceuticals Inc	Estrogen receptor modulators and uses thereof
US9540361B2 (en)	2010-12-24	2017-01-10	Merck Sharp & Dohme B.V.	N-substituted azetidine derivatives
DE102011087987A1 (de)	2011-12-08	2013-06-13	Bayer Intellectual Property Gmbh	6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
KR20150039705A (ko)	2011-12-30	2015-04-13	켄타우루스 바이오파마 컴퍼니 리미티드	신규 아릴알켄 유도체 및 이의 선택성 에스트로겐 수용체 조절제에 있어서의 응용
CN102584687A (zh)	2011-12-30	2012-07-18	北京赛林泰医药技术有限公司	作为选择性雌激素受体调节剂的乙烯衍生物
SI3033086T1 (sl) *	2013-08-14	2022-01-31	Novartis Ag	Kombinirana terapija za zdravljenje raka
WO2015028409A1 (de)	2013-08-27	2015-03-05	Bayer Pharma Aktiengesellschaft	6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN117865872A (zh)	2014-12-18	2024-04-12	豪夫迈·罗氏有限公司	四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CN107406424B (zh)	2014-12-18	2020-08-25	豪夫迈·罗氏有限公司	雌激素受体调节剂及其用途
WO2016146591A1 (en) *	2015-03-16	2016-09-22	Astrazeneca Ab	Combination treatment
AR104068A1 (es) *	2015-03-26	2017-06-21	Hoffmann La Roche	Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
KR102676629B1 (ko) *	2015-04-29	2024-06-18	래디어스 파마슈티컬스, 인코포레이티드	암을 치료하는 방법
CN106924210A (zh) *	2015-12-29	2017-07-07	北京新领先医药科技发展有限公司	一种含有帕布昔利布的胶囊剂及其制备方法
AU2017221083B2 (en) *	2016-02-15	2021-06-24	Sanofi	6,7-dihydro-5H-benzo[7]annulene derivatives as estrogen receptor modulators
SG11201903908PA (en)	2016-11-17	2019-05-30	Sanofi Sa	Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3434272A1 (en) *	2017-07-25	2019-01-30	Sanofi	Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
ES2923412T3 (es)	2018-09-07	2022-09-27	Sanofi Sa	Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
US20200155521A1 (en) *	2018-11-16	2020-05-21	Arqule, Inc.	Pharmaceutical combination for treatment of cancer

2017
- 2017-07-25 EP EP17305998.1A patent/EP3434272A1/en not_active Ceased
2018
- 2018-07-23 RS RS20220068A patent/RS62837B1/sr unknown
- 2018-07-23 LT LTEPPCT/EP2018/069901T patent/LT3658147T/lt unknown
- 2018-07-23 CN CN201880048755.5A patent/CN111107851B/zh active Active
- 2018-07-23 WO PCT/EP2018/069901 patent/WO2019020559A1/en not_active Ceased
- 2018-07-23 HR HRP20212030TT patent/HRP20212030T1/hr unknown
- 2018-07-23 KR KR1020207002003A patent/KR20200031622A/ko not_active Ceased
- 2018-07-23 SI SI201830528T patent/SI3658147T1/sl unknown
- 2018-07-23 BR BR112020001398-6A patent/BR112020001398A2/pt not_active Application Discontinuation
- 2018-07-23 HU HUE18740615A patent/HUE057271T2/hu unknown
- 2018-07-23 CA CA3070754A patent/CA3070754A1/en active Pending
- 2018-07-23 MA MA49673A patent/MA49673B1/fr unknown
- 2018-07-23 DK DK18740615.2T patent/DK3658147T3/da active
- 2018-07-23 JP JP2020503737A patent/JP6741897B1/ja active Active
- 2018-07-23 PL PL18740615T patent/PL3658147T3/pl unknown
- 2018-07-23 SG SG11202000367RA patent/SG11202000367RA/en unknown
- 2018-07-23 US US16/634,089 patent/US11260057B2/en active Active
- 2018-07-23 MX MX2020000917A patent/MX393852B/es unknown
- 2018-07-23 ES ES18740615T patent/ES2906279T3/es active Active
- 2018-07-23 IL IL272166A patent/IL272166B2/en unknown
- 2018-07-23 EP EP18740615.2A patent/EP3658147B1/en active Active
- 2018-07-23 PT PT187406152T patent/PT3658147T/pt unknown
- 2018-07-23 AU AU2018308871A patent/AU2018308871A1/en not_active Abandoned
- 2018-07-23 MY MYPI2020000179A patent/MY195271A/en unknown
- 2018-07-23 RU RU2020107416A patent/RU2764116C2/ru active
- 2018-07-24 AR ARP180102058 patent/AR112284A1/es not_active Application Discontinuation
- 2018-07-24 TW TW107125442A patent/TWI768087B/zh not_active IP Right Cessation
- 2018-07-24 UY UY0001037818A patent/UY37818A/es not_active Application Discontinuation
2020
- 2020-01-09 ZA ZA2020/00145A patent/ZA202000145B/en unknown
- 2020-01-10 PH PH12020500091A patent/PH12020500091A1/en unknown
- 2020-01-13 CO CONC2020/0000240A patent/CO2020000240A2/es unknown
2022
- 2022-01-19 US US17/579,187 patent/US20220362248A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP6741897B1 (ja)	2020-08-19
MX393852B (es)	2025-03-24
KR20200031622A (ko)	2020-03-24
RU2020107416A3 (da)	2021-08-25
UY37818A (es)	2020-08-31
HUE057271T2 (hu)	2022-04-28
CO2020000240A2 (es)	2020-04-24
ES2906279T3 (es)	2022-04-18
BR112020001398A2 (pt)	2020-07-28
PT3658147T (pt)	2022-02-02
MA49673A (fr)	2021-03-24
PH12020500091A1 (en)	2020-09-14
CA3070754A1 (en)	2019-01-31
IL272166B2 (en)	2023-04-01
EP3658147B1 (en)	2021-11-10
US20220362248A1 (en)	2022-11-17
MA49673B1 (fr)	2022-02-28
AU2018308871A1 (en)	2020-02-06
ZA202000145B (en)	2021-07-28
TW201919612A (zh)	2019-06-01
SG11202000367RA (en)	2020-02-27
MY195271A (en)	2023-01-11
US20200171033A1 (en)	2020-06-04
RU2020107416A (ru)	2021-08-25
PL3658147T3 (pl)	2022-03-07
AR112284A1 (es)	2019-10-09
EP3658147A1 (en)	2020-06-03
WO2019020559A1 (en)	2019-01-31
US11260057B2 (en)	2022-03-01
LT3658147T (lt)	2022-01-10
CN111107851A (zh)	2020-05-05
RU2764116C2 (ru)	2022-01-13
RS62837B1 (sr)	2022-02-28
EP3434272A1 (en)	2019-01-30
SI3658147T1 (sl)	2022-02-28
IL272166A (en)	2020-03-31
JP2020526572A (ja)	2020-08-31
HRP20212030T1 (hr)	2022-04-01
TWI768087B (zh)	2022-06-21
IL272166B (en)	2022-12-01
CN111107851B (zh)	2023-05-12

Publication	Publication Date	Title
IL272166A (en)	2020-03-31	A combination containing palbociclib and 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo [7] Anolin-2 carboxylic acid and its use in cancer treatment
ZA202101006B (en)	2022-08-31	Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate
DK3452460T3 (da)	2020-03-16	Heteroaryl-1,2,4-triazol og heteroaryl-tetrazolforbindelser til kontrol af ektoparasitter
LT3880654T (lt)	2022-02-25	2-formil-3-hidroksifeniloksimetilo junginiai, galintys moduliuoti hemoglobiną
DK3515523T3 (da)	2021-05-17	Kardiovaskulart hjælpesystem som kvantificerer hjertefunktion og fremmer hjerterestitution
DK3328843T3 (da)	2023-01-09	1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
LT3746429T (lt)	2022-05-10	(1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai
DK3154959T3 (da)	2019-09-30	1-((3s,4r)-4-(3-fluorphenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urinstof som en trka-kinaseinhibitor
LT3458020T (lt)	2021-02-25	Junginiai, skatinantys plaukų augimą ir (arba) slopinantys arba atitolinantys plaukų slinkimą žmonėms, ir kompozicijos, skirtos tokiam naudojimui
IL287805A (en)	2022-01-01	6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene -2-carboxylic for use in metastatic or advanced breast cancer patients
DK3330258T3 (da)	2021-08-16	1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme
DK2467364T3 (da)	2014-06-30	Nitrogen-holdige forbindelser og farmaceutiske sammensætninger for behandling af atrial flimren.
EP3988046C0 (en)	2025-07-09	BONE CLAMP
IL272001A (en)	2020-02-27	Custom Titanium Alloy, TI-64, 23plus
DK3481819T3 (da)	2022-07-25	Forbindelser og anvendelse deraf til reducering af urisyreniveauer
DK3653613T3 (da)	2022-12-19	1,3-disubstitueret ketenforbindelse og anvendelse deraf
DK3015538T3 (da)	2021-06-14	Desinfektions- og/eller rengøringsmiddel, anvendelse deraf og fremgangsmåde til desinfektion og/eller ren-gøring af overflader, værktøjer og/eller instrumenter
EP3312170A4 (en)	2018-12-12	1,4-di-substituted imidazole derivative
DK4237418T3 (da)	2026-05-04	Pyrimidinforbindelser, sammensætninger og medicinske anvendelser deraf
DK3288825T3 (da)	2019-12-09	Teleskopisk adgangsbro, enhed forsynet hermed og tilhørende fremgangsmåde
DK3471722T3 (da)	2023-12-04	Forbindelser, sammensætninger og fremgangsmåder til forebyggelse og/eller behandling af cancer
EP4003454A4 (en)	2023-07-26	MEDICAL DEPARTMENT, COMPONENTS AND IDENTIFICATION SYSTEM
DK3259255T3 (da)	2021-01-18	(2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre
DK3456712T3 (da)	2022-05-30	Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3092223T3 (da)	2020-03-16	(r)-3-((3s,4s)-3-fluor-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4- methylbenzyl)pyrrolidin-2-on og prodrugs heraf til behandling af psykiatriske forstyrrelser